ArticleFrontiers in pharmacology2026
Antiproteinuric effect of dapagliflozin attenuates tubule-interstitial injury development in subclinical acute kidney injury animal model.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Subclinical acute kidney injury (subAKI) is characterized by markers of tubular injury without changes in glomerular function, being associated with acute kidney injury and chronic kidney disease. The use of dapagliflozin (Dapa) has shown protective effects in different models of kidney diseases. However, its effects on the development of subAKI are still under investigation. Previous results suggested that dapagliflozin effect on proximal tubule epithelial cells may involve protein Methods: Male BALB/c mice (6-8-week-old) were separated in four experimental groups: control (CTL), subAKI, subAKI + Dapa, and Dapa. The subAKI mouse model was induced by albumin overload for 7 days. Treated animals received dapagliflozin (1.0 mg/kg/day) by oral gavage. Renal functional and structural parameters were analyzed. Results: Glomerular structure and function were preserved across all experimental groups. However, subAKI animals exhibited increased albuminuria, urinary β2-microglobulin excretion, and elevated KIM-1 expression, all of which were attenuated by dapagliflozin treatment. In addition, dapagliflozin restored albumin-FITC uptake in the renal cortex of subAKI animals. Consistent with these findings, dapagliflozin prevented the reduction in fluorescein isothiocyanate-conjugated albumin (albumin-FITC) uptake induced by high albumin concentration (20 mg/mL) in LLC-PK1 cells. Furthermore, both (Na Conclusion: These results suggest that the protective effect of dapagliflozin on tubule-interstitial injury development in subAKI is associated with the restoration of total protein
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.